3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Other hematologic neoplasm
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Melanoma
2
Carcinoma, Renal Cell
2
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Sarcoma
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Lung Neoplasms
1
Liver Neoplasms
1
Leukemia
1
Kidney Neoplasms
1
Glioblastoma
1
Esophageal Neoplasms
1
Disease
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Bronchogenic
1
Breast Neoplasms
1
Interventions
pembrolizumab
6
Sorafenib
4
Filgrastim
4
Carboplatin
4
Thiotepa
3
Radiotherapy
3
Psychiatric Rehabilitation
3
Nivolumab
3
Ipilimumab
3
Cyclophosphamide
3
sargramostim
2
ixabepilone
2
fludarabine
2
Temozolomide
2
Sirolimus
2
Polymerase Chain Reaction
2
Peripheral Blood Stem Cell Transplantation
2
Melphalan
2
Ifosfamide
2
Granulocyte Colony-Stimulating Factor
2
Gene Expression Profiling
2
Etoposide
2
Drug Therapy
2
Counseling
2
Busulfan
2
Bupropion
2
Blood Specimen Collection
2
Biopsy
2
vofatamab
1
utomilumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Liver Neoplasms
×
Interleukin-15
×
Genitourinary
×
Clear all
NCT07410676
2026-02-18
EBNK-ST-001
Essen Biotech
Phase 1/2
Recruiting
83 enrolled